抗Bcl2相關(guān)髓細(xì)胞白血病序列1(MCL1)多克隆抗體
Anti-Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Polyclonal Antibody
EAT; MCL1L; MCL1S; BCL2L3; TM; Myeloid Cell Leukemia Sequence 1, Bcl2 Related; Bcl-2-like protein 3; Bcl-2-related protein EAT/mcl1; mcl1/EAT
- 編號(hào)FAC615Hu01
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 效價(jià)-
- Ig類型IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 激發(fā)波長(zhǎng)-
- 單次使用量1-5 μl
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 且適物種-
- 應(yīng)用FCM
- 下載英文說明書 中文說明書
- 規(guī)格25test50test100test200test500test
- 價(jià)格¥ 792¥ 1320¥ 2112¥ 2640¥ 4620
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Human Raji cell line was fixed with 2% paraformaldehyde (10 min) , permeabilised with 0.1% BSA-Triton X-100,then stained with 20μg/ml rabbit Anti-human MCL1 Polyclonal Antibody (Catalog FAC615Hu01, red histogram) or Isotype control antibody (Catalog IS067-Rb01, green histogram), followed by 1μg/ml FITC-conjugated Anti-rabbit IgG Secondary Antibody (Catalog SAA544Rb18).
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
用法
For flow cytometry, the suggested use of this reagent is 1-5 μl per 10^6 cells in 100 μl volume.
Optimal working dilutions could be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過一年。避免反復(fù)凍融。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPC615Hu01 | Bcl2相關(guān)髓細(xì)胞白血病序列1(MCL1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC615Hu01 | Bcl2相關(guān)髓細(xì)胞白血病序列1(MCL1)多克隆抗體 | WB; FCM |
| FAC615Hu01 | 抗Bcl2相關(guān)髓細(xì)胞白血病序列1(MCL1)多克隆抗體 | FCM |
| MAC615Hu22 | Bcl2相關(guān)髓細(xì)胞白血病序列1(MCL1)單克隆抗體 | WB; IHC; ICC; IP. |
| SEC615Hu | Bcl2相關(guān)髓細(xì)胞白血病序列1(MCL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMC615Hu | Bcl2相關(guān)髓細(xì)胞白血病序列1(MCL1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia[Pubmed: 31718075] |
| ACTA NEUROPATHOLOGICA COMMUNICATIONS | Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma[Pubmed: 32410663] |
| Cancers (Basel) | BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581[33540760] |